StockNews.AI
TMCI
StockNews.AI
117 days

Treace to Report First Quarter 2025 Financial Results on May 8, 2025

1. Treace will announce Q1 2025 financial results on May 8. 2. Company expects to discuss advancements in bunion treatment technologies. 3. Approximately 67 million Americans are affected by bunions. 4. Treace aims to improve surgical care for bunions and midfoot deformities. 5. New products and systems are set to expand Treace's market footprint.

5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results and product innovations suggest strong growth potential, reflecting positively on TMCI.

How important is it?

Financial results and product advancements directly influence investor sentiment and stock price.

Why Short Term?

Immediate investor interest expected around the Q1 earnings announcement and product developments.

Related Companies

ZBHSYKNUVA
April 24, 2025 16:05 ET  | Source: Treace Medical Concepts, Inc. PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/. Internet Posting of Information Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.  To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram. Contacts:Treace Medical ConceptsMark L. HairChief Financial Officermhair@treace.net(904) 373-5940 Investors:Gilmartin GroupPhilip Trip TaylorIR@treace.net

Related News